Opinion|Videos|October 14, 2024

Unmet Needs and Clinical Considerations for HER2+ NSCLC

Key Takeaways

  • Effective therapies that penetrate the blood-brain barrier and target resistant tumor cells are needed in lung cancer brain metastases management.
  • Current treatments often provide limited survival benefits and significant side effects, highlighting the need for improved therapeutic options.
SHOW MORE

Panelists discuss how persistent unmet needs in HER2-directed therapy for NSCLC present opportunities for future research and pipeline therapies, potentially addressing challenges such as treatment resistance, improved efficacy, or reduced toxicity profiles.

Video content above is prompted by the following:

  • What unmet needs persist in this space and what opportunities exist for future research or pipeline therapies?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo